{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,2,18]],"date-time":"2023-02-18T05:07:42Z","timestamp":1676696862221},"reference-count":43,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T00:00:00Z","timestamp":1676332800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T00:00:00Z","timestamp":1676332800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Innere Medizin"],"DOI":"10.1007\/s00108-023-01476-3","type":"journal-article","created":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T11:52:15Z","timestamp":1676375535000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Interstitielle Lungenerkrankungen"],"prefix":"10.1007","author":[{"given":"Christoph","family":"Lederer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katharina","family":"Buschulte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernhard","family":"Hellmich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claus Peter","family":"Heu\u00dfel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Kriegsmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Polke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Kreuter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,2,14]]},"reference":[{"key":"1476_CR1","unstructured":"S1-Leitlinie Interdisziplin\u00e4re Diagnostik interstitieller Lungenerkrankungen im Erwachsenenalter. https:\/\/register.awmf.org\/de\/leitlinien\/detail\/020-028"},{"key":"1476_CR2","first-page":"152","volume":"118","author":"M Kreuter","year":"2021","unstructured":"Kreuter\u00a0M, M\u00fcller-Ladner\u00a0U, Costabel\u00a0U, Jonigk\u00a0D, Heu\u00dfel\u00a0CP (2021) Diagnostik und Therapie der Lungenfibrosen. Dtsch Arztebl 118:152\u2013162","journal-title":"Dtsch Arztebl"},{"key":"1476_CR3","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1164\/rccm.201308-1483ST","volume":"188","author":"WD Travis","year":"2013","unstructured":"Travis\u00a0WD, Costabel\u00a0U, Hansell\u00a0DM et\u00a0al (2013) An official American thoracic society\/European respiratory society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 188:733\u2013748","journal-title":"Am J Respir Crit Care Med"},{"key":"1476_CR4","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1055\/s-0044-100207","volume":"72","author":"M Kreuter","year":"2018","unstructured":"Kreuter\u00a0M, Ochmann\u00a0U, Koschel\u00a0D et\u00a0al (2018) Patientenfragebogen zur Erfassung der Ursachen interstitieller und seltener Lungenerkrankungen \u2013 klinische Sektion der DGP. Pneumologie 72:446\u2013457","journal-title":"Pneumologie"},{"key":"1476_CR5","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1159\/000504677","volume":"99","author":"M Polke","year":"2020","unstructured":"Polke\u00a0M, Kirsten\u00a0D, Teucher\u00a0B et\u00a0al (2020) A comparison of existing questionnaires for identifying the causes of interstitial and rare lung diseases. Respiration 99:119\u2013124","journal-title":"Respiration"},{"key":"1476_CR6","volume-title":"Seltene Lungenerkrankungen","author":"M Kreuter","year":"2021","unstructured":"Kreuter\u00a0M, Costabel\u00a0U, Herth\u00a0F, Kirsten\u00a0D (2021) Seltene Lungenerkrankungen. Springer, Berlin, Heidelberg"},{"key":"1476_CR7","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/S2213-2600(19)30342-X","volume":"8","author":"LK Troy","year":"2020","unstructured":"Troy\u00a0LK, Grainge\u00a0C, Corte\u00a0TJ et\u00a0al (2020) Diagnostic accuracy of transbronchial lung cryobiopsy for interstitial lung disease diagnosis (COLDICE): a\u00a0prospective, comparative study. Lancet Respir Med 8:171\u2013181","journal-title":"Lancet Respir Med"},{"key":"1476_CR8","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1002\/art.30423","volume":"63","author":"J Le Pavec","year":"2011","unstructured":"Le Pavec\u00a0J, Girgis\u00a0RE, Lechtzin\u00a0N et al (2011) Systemic sclerosis-related pulmonary hypertension associated with interstitial lung disease: impact of pulmonary arterial hypertension therapies. Arthritis Rheum 63:2456\u20132464","journal-title":"Arthritis Rheum"},{"key":"1476_CR9","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1378\/chest.13-2626","volume":"146","author":"TA Winstone","year":"2014","unstructured":"Winstone\u00a0TA, Assayag\u00a0D, Wilcox\u00a0PG et al (2014) Predictors of mortality and progression in scleroderma-associated interstitial lung disease: a\u00a0systematic review. Chest 146:422\u2013436","journal-title":"Chest"},{"key":"1476_CR10","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1183\/13993003.00150-2015","volume":"46","author":"A Fischer","year":"2015","unstructured":"Fischer\u00a0A, Antoniou\u00a0KM, Brown\u00a0KK et\u00a0al (2015) An official European respiratory society\/American thoracic society research statement: interstitial pneumonia with autoimmune features. Eur Respir\u00a0J 46:976\u2013987","journal-title":"Eur Respir J"},{"key":"1476_CR11","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1159\/000079633","volume":"71","author":"P Camus","year":"2004","unstructured":"Camus\u00a0P, Fanton\u00a0A, Bonniaud\u00a0P et\u00a0al (2004) Interstitial lung disease induced by drugs and radiation. Respiration 71:301\u2013326","journal-title":"Respiration"},{"key":"1476_CR12","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/S0272-5231(03)00144-8","volume":"25","author":"P Camus","year":"2004","unstructured":"Camus\u00a0P, Martin\u00a0WJ, Rosenow\u00a0EC (2004) Amiodarone pulmonary toxicity. Clin Chest Med 25:65\u201375","journal-title":"Clin Chest Med"},{"key":"1476_CR13","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S0272-5231(03)00143-6","volume":"25","author":"U Costabel","year":"2004","unstructured":"Costabel\u00a0U, Uzaslan\u00a0E, Guzman\u00a0J (2004) Bronchoalveolar lavage in drug-induced lung disease. Clin Chest Med 25:25\u201335","journal-title":"Clin Chest Med"},{"issue":"2","key":"1476_CR14","doi-asserted-by":"publisher","first-page":"1602419","DOI":"10.1183\/13993003.02419-2016","volume":"50","author":"B Duchemann","year":"2017","unstructured":"Duchemann\u00a0B, Annesi-Maesano\u00a0I, Jacobe De Naurois\u00a0C et al (2017) Prevalence and incidence of interstitial lung diseases in a\u00a0multi-ethnic county of Greater Paris. Eur Respir\u00a0J 50(2):1602419","journal-title":"Eur Respir J"},{"issue":"150","key":"1476_CR15","doi-asserted-by":"publisher","first-page":"180077","DOI":"10.1183\/16000617.0077-2018","volume":"27","author":"AL Olson","year":"2018","unstructured":"Olson\u00a0AL, Gifford\u00a0AH, Inase\u00a0N et al (2018) The epidemiology of idiopathic pulmonary fibrosis and interstitial lung diseases at risk of a\u00a0progressive-fibrosing phenotype. Eur Respir Rev 27(150):180077. https:\/\/doi.org\/10.1183\/16000617.0077-2018","journal-title":"Eur Respir Rev"},{"key":"1476_CR16","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1055\/a-1120-3531","volume":"74","author":"J Behr","year":"2020","unstructured":"Behr\u00a0J, G\u00fcnther\u00a0A, Bonella\u00a0F et\u00a0al (2020) S2K Leitlinie zur Diagnostik der Idiopathischen Lungenfibrose. Pneumologie 74:263\u2013293","journal-title":"Pneumologie"},{"key":"1476_CR17","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00692-2018","author":"AU Wells","year":"2018","unstructured":"Wells\u00a0AU, Brown\u00a0KK, Flaherty\u00a0KR et\u00a0al (2018) What\u2019s in a name? That which we call IPF, by any other name would act the same. Eur Respir\u00a0J. https:\/\/doi.org\/10.1183\/13993003.00692-2018","journal-title":"Eur Respir J"},{"key":"1476_CR18","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1164\/ajrccm.150.5.7952555","volume":"150","author":"PE Bettencourt","year":"1994","unstructured":"Bettencourt\u00a0PE, Del Bono\u00a0EA, Spiegelman\u00a0D et\u00a0al (1994) Clinical utility of chest auscultation in common pulmonary diseases. Am J Respir Crit Care Med 150:1291\u20131297","journal-title":"Am J Respir Crit Care Med"},{"issue":"155","key":"1476_CR19","doi-asserted-by":"publisher","first-page":"190146","DOI":"10.1183\/16000617.0146-2019","volume":"29","author":"FF Rahaghi","year":"2020","unstructured":"Rahaghi\u00a0FF, Baughman\u00a0RP, Saketkoo\u00a0LA et\u00a0al (2020) Delphi consensus recommendations for a\u00a0treatment algorithm in pulmonary sarcoidosis. Eur Respir Rev 29(155):190146. https:\/\/doi.org\/10.1183\/16000617.0146-2019","journal-title":"Eur Respir Rev"},{"key":"1476_CR20","doi-asserted-by":"publisher","first-page":"e36","DOI":"10.1164\/rccm.202005-2032ST","volume":"202","author":"G Raghu","year":"2020","unstructured":"Raghu\u00a0G, Remy-Jardin\u00a0M, Ryerson\u00a0CJ et al (2020) Diagnosis of hypersensitivity pneumonitis in adults. An official ATS\/JRS\/ALAT clinical practice guideline. Am J Respir Crit Care Med 202:e36\u2013e69","journal-title":"Am J Respir Crit Care Med"},{"key":"1476_CR21","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/j.amjmed.2003.12.030","volume":"116","author":"JS Vourlekis","year":"2004","unstructured":"Vourlekis\u00a0JS, Schwarz\u00a0MI, Cherniack\u00a0RM et\u00a0al (2004) The effect of pulmonary fibrosis on survival in patients with hypersensitivity pneumonitis. Am J Med 116:662\u2013668","journal-title":"Am J Med"},{"key":"1476_CR22","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1016\/S2213-2600(17)30383-1","volume":"5","author":"M Kreuter","year":"2017","unstructured":"Kreuter\u00a0M, Bendstrup\u00a0E, Russell\u00a0AM et\u00a0al (2017) Palliative care in interstitial lung disease: living well. Lancet Respir Med 5:968\u2013980","journal-title":"Lancet Respir Med"},{"key":"1476_CR23","first-page":"797","volume":"379","author":"DJ Lederer","year":"2018","unstructured":"Lederer\u00a0DJ, Martinez\u00a0FJ (2018) Idiopathic pulmonary fibrosis. N\u00a0Engl J Med 379:797\u2013798","journal-title":"N Engl J Med"},{"key":"1476_CR24","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1513\/AnnalsATS.202112-1359OC","volume":"19","author":"P Marijic","year":"2022","unstructured":"Marijic\u00a0P, Schwarzkopf\u00a0L, Maier\u00a0W et\u00a0al (2022) Effects of influenza vaccination in patients with interstitial lung diseases: an epidemiological claims data analysis. Annals ATS 19:1479\u20131488","journal-title":"Annals ATS"},{"issue":"8","key":"1476_CR25","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1007\/s00393-021-01067-3","volume":"80","author":"K Buschulte","year":"2021","unstructured":"Buschulte\u00a0K, Hoffmann-Vold\u00a0A, Dobrota\u00a0R, H\u00f6ger\u00a0P, Krause\u00a0A, Kreuter\u00a0M (2021) Therapie von Lungenfibrosen bei rheumatischen Systemerkrankungen (neue Therapien). Z\u00a0Rheumatol 80(8):743\u2013754","journal-title":"Z Rheumatol"},{"key":"1476_CR26","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","volume":"4","author":"DP Tashkin","year":"2016","unstructured":"Tashkin\u00a0DP, Roth\u00a0MD, Clements\u00a0PJ et al (2016) Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a\u00a0randomised controlled, double-blind, parallel group trial. Lancet Respir Med 4:708\u2013719","journal-title":"Lancet Respir Med"},{"key":"1476_CR27","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/S2213-2600(20)30318-0","volume":"8","author":"D Khanna","year":"2020","unstructured":"Khanna\u00a0D, Lin\u00a0CJF, Furst\u00a0DE et al (2020) Tocilizumab in systemic sclerosis: a\u00a0randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med 8:963\u2013974","journal-title":"Lancet Respir Med"},{"key":"1476_CR28","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1002\/art.41668","volume":"73","author":"D Roofeh","year":"2021","unstructured":"Roofeh\u00a0D, Lin\u00a0CJF, Goldin\u00a0J et al (2021) Tocilizumab prevents progression of early systemic sclerosis-associated interstitial lung disease. Arthritis Rheumatol 73:1301\u20131310","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"1476_CR29","doi-asserted-by":"publisher","first-page":"2000337","DOI":"10.1183\/13993003.00337-2020","volume":"57","author":"PA Juge","year":"2021","unstructured":"Juge\u00a0PA, Lee\u00a0JS, Lau\u00a0J et\u00a0al (2021) Methotrexate and rheumatoid arthritis associated interstitial lung disease. Eur Respir\u00a0J 57(2):2000337. https:\/\/doi.org\/10.1183\/13993003.00337-2020","journal-title":"Eur Respir J"},{"key":"1476_CR30","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1007\/s10067-017-3707-5","volume":"36","author":"J Rojas-Serrano","year":"2017","unstructured":"Rojas-Serrano\u00a0J, Herrera-Bringas\u00a0D, Perez-Roman\u00a0DI et al (2017) Rheumatoid arthritis-related interstitial lung disease (RA-ILD): methotrexate and the severity of lung disease are associated to prognosis. Clin Rheumatol 36:1493\u20131500","journal-title":"Clin Rheumatol"},{"key":"1476_CR31","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1093\/rheumatology\/keab317","volume":"61","author":"C Fernandez-Diaz","year":"2021","unstructured":"Fernandez-Diaz\u00a0C, Atienza-Mateo\u00a0B, Castaneda\u00a0S et al (2021) Abatacept in monotherapy vs combined in interstitial lung disease of rheumatoid arthritis-multicentre study of 263 Caucasian patients. Rheumatology 61:299\u2013308","journal-title":"Rheumatology"},{"key":"1476_CR32","doi-asserted-by":"publisher","first-page":"2229","DOI":"10.1056\/NEJMoa042976","volume":"353","author":"M Demedts","year":"2005","unstructured":"Demedts\u00a0M, Behr\u00a0J, Buhl\u00a0R et al (2005) High-dose acetylcysteine in idiopathic pulmonary fibrosis. N\u00a0Engl J Med 353:2229\u20132242","journal-title":"N Engl J Med"},{"key":"1476_CR33","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1056\/NEJMoa1113354","volume":"366","author":"G Raghu","year":"2012","unstructured":"Idiopathic Pulmonary Fibrosis Clinical Research Network, Raghu\u00a0G, Anstrom\u00a0KJ et al (2012) Prednisone, azathioprine, and N\u2011acetylcysteine for pulmonary fibrosis. N\u00a0Engl J Med 366:1968\u20131977","journal-title":"N Engl J Med"},{"key":"1476_CR34","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1055\/a-1179-2905","volume":"74","author":"J Behr","year":"2020","unstructured":"Behr\u00a0J, Gunther\u00a0A, Bonella\u00a0F et\u00a0al (2020) German guideline for idiopathic pulmonary fibrosis. Pneumologie 74:e1\u2013e2","journal-title":"Pneumologie"},{"key":"1476_CR35","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1055\/s-0043-106160","volume":"71","author":"J Behr","year":"2017","unstructured":"Behr\u00a0J, Gunther\u00a0A, Bonella\u00a0F et\u00a0al (2017) German guideline for idiopathic pulmonary fibrosis\u2014update on pharmacological therapies 2017. Pneumologie 71:460\u2013474","journal-title":"Pneumologie"},{"key":"1476_CR36","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1056\/NEJMoa1402582","volume":"370","author":"TE King Jr.","year":"2014","unstructured":"King\u00a0TE Jr., Bradford\u00a0WZ, Castro-Bernardini\u00a0S et al (2014) A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N\u00a0Engl J Med 370:2083\u20132092","journal-title":"N Engl J Med"},{"key":"1476_CR37","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1016\/S0140-6736(11)60405-4","volume":"377","author":"PW Noble","year":"2011","unstructured":"Noble\u00a0PW, Albera\u00a0C, Bradford\u00a0WZ et\u00a0al (2011) Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 377:1760\u20131769","journal-title":"Lancet"},{"key":"1476_CR38","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","volume":"370","author":"L Richeldi","year":"2014","unstructured":"Richeldi\u00a0L, du Bois\u00a0RM, Raghu\u00a0G et\u00a0al (2014) Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N\u00a0Engl J Med 370:2071\u20132082","journal-title":"N Engl J Med"},{"key":"1476_CR39","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1164\/rccm.202202-0399ST","volume":"205","author":"G Raghu","year":"2022","unstructured":"Raghu\u00a0G, Remy-Jardin\u00a0M, Richeldi\u00a0L et al (2022) Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS\/ERS\/JRS\/ALAT clinical practice guideline. Am J Respir Crit Care Med 205:e18\u2013e47","journal-title":"Am J Respir Crit Care Med"},{"key":"1476_CR40","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","volume":"380","author":"O Distler","year":"2019","unstructured":"Distler\u00a0O, Highland\u00a0KB, Gahlemann\u00a0M et al (2019) Nintedanib for systemic sclerosis-associated interstitial lung disease. N\u00a0Engl J Med 380:2518\u20132528","journal-title":"N Engl J Med"},{"key":"1476_CR41","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","volume":"381","author":"KR Flaherty","year":"2019","unstructured":"Flaherty\u00a0KR, Wells\u00a0AU, Cottin\u00a0V et\u00a0al (2019) Nintedanib in progressive fibrosing interstitial lung diseases. N\u00a0Engl J Med 381:1718\u20131727","journal-title":"N Engl J Med"},{"key":"1476_CR42","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/S2213-2600(20)30554-3","volume":"9","author":"J Behr","year":"2021","unstructured":"Behr\u00a0J, Prasse\u00a0A, Kreuter\u00a0M et al (2021) Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a\u00a0double-blind, randomised, placebo-controlled, phase 2b trial. Lancet Respir Med 9:476\u2013486","journal-title":"Lancet Respir Med"},{"key":"1476_CR43","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1186\/s12931-022-02143-1","volume":"23","author":"P Marijic","year":"2022","unstructured":"Marijic\u00a0P, Schwarzkopf\u00a0L, Maier\u00a0W et al (2022) Comparing outcomes of ILD patients managed in specialised versus non-specialised centres. Respir Res 23:220","journal-title":"Respir Res"}],"container-title":["Die Innere Medizin"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-023-01476-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00108-023-01476-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-023-01476-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,17]],"date-time":"2023-02-17T05:55:09Z","timestamp":1676613309000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00108-023-01476-3"}},"subtitle":["Klassifikation, Differenzialdiagnostik und therapeutische Ans\u00e4tze bei einer heterogenen Gruppe chronischer Lungenerkrankungen"],"short-title":[],"issued":{"date-parts":[[2023,2,14]]},"references-count":43,"alternative-id":["1476"],"URL":"https:\/\/doi.org\/10.1007\/s00108-023-01476-3","relation":{},"ISSN":["2731-7080","2731-7099"],"issn-type":[{"value":"2731-7080","type":"print"},{"value":"2731-7099","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,14]]},"assertion":[{"value":"5 January 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Gem\u00e4\u00df den Richtlinien des Springer Medizin Verlags werden Autoren und Wissenschaftliche Leitung im Rahmen der Manuskripterstellung und Manuskriptfreigabe aufgefordert, eine vollst\u00e4ndige Erkl\u00e4rung zu ihren finanziellen und nichtfinanziellen Interessen abzugeben.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"<b>M.\u00a0Kreuter<\/b>: A.\u00a0Finanzielle Interessen: Mein Arbeitgeber f\u00fcr Forschung von Roche und Boehringer Ingelheim.\u00a0\u2013 Referent: Roche und Boehringer Ingelheim.\u00a0\u2013 Beratung: Roche und Boehringer Ingelheim.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: Sektionsleiter, Thoraxklinik und \u00e4rztl. Direktor Pneumologie, RKH Klinikum Ludwigsburg | Mitgliedschaften: ERS, DGP. <b>C.\u00a0Lederer<\/b>: A.\u00a0Finanzielle Interessen: C.\u00a0Lederer gibt an, dass kein finanzieller Interessenkonflikt besteht.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: Assistenzarzt der Abteilung Pneumologie und Beatmungsmedizin (Chefarzt: Prof. Dr. med. Felxi Herth), Thoraxklinik Heidelberg, Universit\u00e4tsklinikum Heidelberg | Mitgliedschaften: Deutsche Gesellschaft f\u00fcr Pneumologie (DGP), European Respiratory Society (ERS), jeweils einfaches Mitglied. <b>C.\u00a0P. Heu\u00dfel<\/b>: A.\u00a0Finanzielle Interessen: Foschungsf\u00f6rderung von folgenden Unternehmen\/Organisationen: Siemens 2012\u20132014; Pfizer 2012\u20132014; MeVis 2012, 2013; Boehringer Ingelheim 2014; German Center for Lung Research 2011ff.\u00a0\u2013 Honararempf\u00e4nger von folgenden Unternehmen: Gilead 2008\u20132014; Essex 2008, 2009, 2010; Schering-Plough 2008, 2009, 2010; AstraZeneca 2008\u20132014, 2022; Lilly 2008, 2009, 2012; Roche 2008, 2009; MSD 2009\u20132014; Pfizer 2010\u20132014; Bracco 2010, 2011; MEDA Pharma 2011; Intermune 2011\u20132014; Chiesi 2012; Siemens 2012 | Covidien 2012; Pierre Fabre 2012; Boehringer Ingelheim 2012, 2013, 2022; Grifols 2012; Novartis 2013\u20132016; Basilea 2015, 2016; Bayer 2016.\u00a0\u2013 Beraterzuwendungen von folgenden Unternehmen:: Schering-Plough 2009, 2010; Pfizer 2008\u20132014; Basilea 2008, 2009, 2010; Boehringer Ingelheim 2010\u20132014; Novartis 2010, 2012, 2014; Roche 2010; Astellas 2011, 2012; Gilead 2011\u20132015; MSD 2011\u20132013; Lilly 2011; Intermune 2013\u20132014; Fresenius 2013, 2014.\u00a0\u2013 Aktien von GSK; Patenthalter von Method and Device For Representing the Microstructure of the Lungs. IPC8 Class: AA61B5055FI, PAN: 20080208038, Inventors: W\u00a0Schreiber, U\u00a0Wolf, AW Scholz, CP Heussel.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: Berufliche Position: Chefarzt der Abteilung Diagnostische und Interventionelle Radiologie mit Nuklearmedizin, Thoraxklinik Heidelberg, Universit\u00e4tsklinikum Heidelberg | Mitgliedschaft: Deutsches Zentrum f\u00fcr Lungenforschung (DZL) | Ausschuss-Mitgliedschaften: Chest working group of the German Roentgen society | National guidelines: bronchial carcinoma, mesothelioma, COPD, screening for bronchial carcinoma, CT and MR imaging of the chest, Pneumonia; Consultant of ECIL\u20113, ECCMID, EORTC\/MSG | Guideline for diagnosis of infections in immunocompromized hosts; Founding member of the working team in infections in immunocompromized hosts of the German society of Hematology\/Oncology | Guideline for diagnosis of infections in immunocompromized hosts; Faculty member of European Society of Thoracic Radiology (ESTI), European Respiratory Society (ERS), and member in EIBALL (European Imaging Biomarkers Alliance); Editor of \u201eMedizinische Klinik, Intensivmedizin und Notfallmedizin\u201c, at Springer publishing. <b>K.\u00a0Buschulte<\/b>: A.\u00a0Finanzielle Interessen: Sarkoidose-Netzwerk e.\u202fV. (finanzielle Forschungsf\u00f6rderung).\u00a0\u2013 Vortragshonorar:Boehringer-Ingelheim.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: Angestellte Pneumologin, Thoraxklinik, Heidelberg | Mitgliedschaften: DGP, ERS. <b>M.\u00a0Kriegsmann<\/b>: A.\u00a0Finanzielle Interessen: Vortragshonorare von B\u00f6hringer Ingelheim.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: Angestellter Oberarzt am Institut f\u00fcr Pathologie des Universit\u00e4tsklinikums Heidelberg (zum Zeitpunkt der Manuskripterstellung). <b>M.\u00a0Polke<\/b>: A.\u00a0Finanzielle Interessen: K&L Kongress-Update GmbH\u00a0\u2013 Honorar f\u00fcr Vortr\u00e4ge | Boehringer Ingelheim\u00a0\u2013 Teilnahmegeb\u00fchr Kongress.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: Angestellter Arzt (Oberarzt) in der Thoraxklinik am Universit\u00e4tsklinikum Heidelberg | Mitgliedschaften: Deutsche Gesellschaft f\u00fcr Pneumologie und Beatmungsmedizin, European Respiratory Society. <b>B.\u00a0Hellmich<\/b>: A.\u00a0Finanzielle Interessen: Boehringer: Honorar f\u00fcr Vortr\u00e4ge auf Fachsymposien und Honorar f\u00fcr Teilnahme an einem Advisory Board.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: Chefarzt der Klinik f\u00fcr Innere Medizin, Rheumatologie und Immunologie der Medius Kliniken gGmbH Kirchheim-Teck | Mitgliedschaften: Deutsche Gesellschaft f\u00fcr Innere Medizin, Deutsche Gesellschaft f\u00fcr Rheumatologie, Deutsche Gesellschaft f\u00fcr Diabetologie, Vorstandsmitglied des Verbands rheumatologischer Akutkliniken e.\u202fV., Mitglied der Kommission Leitlinien der Deutschen Gesellschaft f\u00fcr Rheumatologie.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Autorinnen und Autoren"}},{"value":"Die vollst\u00e4ndige Erkl\u00e4rung zum Interessenkonflikt der Wissenschaftlichen Leitung finden Sie am Kurs der zertifizierten Fortbildung auf ExternalRef removed.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Wissenschaftliche Leitung"}},{"value":"erkl\u00e4rt, dass f\u00fcr die Publikation dieser CME-Fortbildung keine Sponsorengelder an den Verlag flie\u00dfen.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}